Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 185, Pu-An Road, Shanghai 200021, China ; Department of Neurology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Department of Neurology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Chin Med. 2013 Jul 27;8:14. doi: 10.1186/1749-8546-8-14. eCollection 2013.
This study aimed to evaluate the effects of add-on Yang-Xue-Qing-Nao granules (YXQN) on sleep dysfunction in patients with Parkinson's disease (PD).
PD participants fitted with an actigraph took either YXQN or placebo granules in a randomized manner for 12 weeks while maintaining other anti-parkinsonism medications (e.g., dopaminergic agent, dopamine agonist) unchanged. Additional participants without sleep disturbance or PD served as controls. The changes in detrended fluctuation analysis (DFA) of physical activity with respect to diurnal activity (DA), evening activity (EA), nocturnal activity (NA), Parkinson's disease sleep scale (PDSS) score and unified Parkinson's disease rating scale (UPDRS) score were evaluated every 4 weeks during the 12-week YXQN intervention period and again at week 16.
A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction (mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study. Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score (p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16, respectively.
YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.
本研究旨在评估加味养血醒脑颗粒（YXQN）对帕金森病（PD）患者睡眠障碍的影响。
佩戴活动记录仪的 PD 参与者以随机方式服用 YXQN 或安慰剂颗粒，同时保持其他抗帕金森病药物（如多巴胺能药物、多巴胺激动剂）不变。无睡眠障碍或 PD 的其他参与者作为对照。在 12 周的 YXQN 干预期间的每 4 周和第 16 周评估身体活动的去趋势波动分析（DFA）相对于日间活动（DA）、傍晚活动（EA）、夜间活动（NA）、帕金森病睡眠量表（PDSS）评分和统一帕金森病评定量表（UPDRS）评分的变化。
共有 61 名（安慰剂组，n = 30；YXQN 组，n = 31）有睡眠障碍的特发性 PD 参与者（平均年龄 ± 标准差，63.4 ± 8.6 岁；平均病程，5.8 ± 6.6 年）完成了这项研究。在 YXQN 组中，EA（p = 0.033，0.037 和 0.029）、DA（p = 0.041，0.038 和 0.027）和 PDSS 评分（p = 0.034，0.028 和 0.029）在第 8 周和第 12 周显著改善，并分别持续到第 16 周。
YXQN 改善了 PD 参与者的 DFA 参数以及 PDSS 和 UPDRS 评分。
